Cargando…

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases

Detalles Bibliográficos
Autores principales:	von Knethen, Andreas, Rodriguez-Barbosa, Jose-Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581460/ https://www.ncbi.nlm.nih.gov/pubmed/34777402 http://dx.doi.org/10.3389/fimmu.2021.795495

Ejemplares similares

Editorial: Role of Neutrophils in Inflammatory Diseases
por: Marichal, Thomas, et al.
Publicado: (2020)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
por: Chong, Pei Pei, et al.
Publicado: (2022)

Editorial: The Role of the Gut Microbiota in Health and Inflammatory Diseases
por: Mangalam, Ashutosh K., et al.
Publicado: (2020)

Editorial: Immunomodulatory role of metalloproteases in chronic inflammatory diseases
por: Yang, Guan-Jun, et al.
Publicado: (2023)

Editorial: Role of stem cell derivatives in inflammatory diseases
por: Zhang, Cuiping, et al.
Publicado: (2023)

Editorial: “The Role of Immune Checkpoint Molecules in Solid and Hematopoietic Stem Cell Transplantation”
por: Kordelas, Lambros, et al.
Publicado: (2021)

Editorial: Role of Macrophage MicroRNAs in Inflammatory Diseases and Cancer
por: Renaudineau, Yves, et al.
Publicado: (2021)

Unraveling the Role of Immune Checkpoints in Leishmaniasis
por: de Freitas e Silva, Rafael, et al.
Publicado: (2021)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
por: Riva, Antonio
Publicado: (2023)

Histone Deacetylation Inhibitors as Therapy Concept in Sepsis
por: von Knethen, Andreas, et al.
Publicado: (2019)

Editorial: Intestinal Dysbiosis in Inflammatory Diseases
por: de Oliveira, Gislane Lelis Vilela, et al.
Publicado: (2021)

Editorial: Inflammatory Mechanisms of Hemolytic Diseases
por: Sesti-Costa, Renata, et al.
Publicado: (2022)

Editorial: Microbiota in skin inflammatory diseases
por: Park, Eun Jeong, et al.
Publicado: (2023)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review
por: Seliger, Barbara
Publicado: (2019)

Editorial: Dual role of inflammatory mediators in cancer immunotherapy
por: Wang, Xiaoli, et al.
Publicado: (2023)

Editorial: Global excellence in inflammatory diseases: Latin America 2021
por: Lima-Júnior, Roberto César Pereira, et al.
Publicado: (2023)

Editorial: ILC checkpoints: expression and functions in physiological and pathological conditions
por: Mariotti, Francesca Romana, et al.
Publicado: (2023)

Editorial: Metabolic conditions of chronic inflammatory diseases
por: Saalbach, Anja, et al.
Publicado: (2022)

Editorial: Targeting signalling pathways in inflammatory diseases
por: Baig, Mirza S., et al.
Publicado: (2023)

Editorial: JAK inhibition in autoimmune and inflammatory diseases
por: Telliez, Jean-Baptiste, et al.
Publicado: (2022)

Editorial: Novel insights into inflammatory roles of mast cells and basophils
por: Tanaka, Satoshi, et al.
Publicado: (2023)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
por: Leblanc, Julie, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Editorial: Immunity and Inflammatory Response in Kidney Stone Disease
por: Thongboonkerd, Visith, et al.
Publicado: (2021)

Editorial: Microbial and Environmental Factors in Autoimmune and Inflammatory Diseases
por: Arleevskaya, Marina I., et al.
Publicado: (2017)

Editorial: Regulation of osteoclast differentiation in autoimmune and inflammatory diseases
por: Lee, Sun-Kyeong, et al.
Publicado: (2023)

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
por: Tong, Huan, et al.
Publicado: (2022)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Editorial: Inflammatory and inflammatory-like responses in insects
por: Goto, Akira, et al.
Publicado: (2023)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9l02dc1gg5amesj94ke51klnno